EPOGEN/PROCRIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPOGEN/PROCRIT (EPOGEN/PROCRIT).
Erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor on erythroid progenitor cells, stimulating proliferation and differentiation into mature red blood cells.
| Metabolism | Metabolized by proteolytic degradation into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Primarily hepatic metabolism; ~10% excreted unchanged in urine. Fecal elimination negligible. |
| Half-life | Terminal half-life: ~4-13 hours in healthy subjects; prolonged to 13-28 hours in chronic kidney disease or on dialysis (due to reduced clearance). |
| Protein binding | Approximately 50% bound to serum proteins; no specific binding protein identified. |
| Volume of Distribution | Vd = 0.03–0.06 L/kg, approximating plasma volume; indicates limited extravascular distribution. |
| Bioavailability | Subcutaneous: ~20-30% compared to IV. |
| Onset of Action | Subcutaneous: reticulocyte count increases in 3-7 days; IV: similar onset but peak levels faster. |
| Duration of Action | Duration of erythropoietic effect: 1-2 weeks after single dose; sustained with repeated dosing. Clinical effect monitored by hemoglobin rise over 2-6 weeks. |
50-100 units/kg intravenously or subcutaneously three times weekly. Initial dose 50 units/kg three times weekly; adjust to maintain hemoglobin target (usually 10-12 g/dL).
| Dosage form | VIAL |
| Renal impairment | No standard GFR-based adjustment for epoetin alfa; dosing is based on hemoglobin response. In chronic kidney disease, initiate when hemoglobin <10 g/dL; titrate to avoid hemoglobin >11 g/dL. |
| Liver impairment | No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment; monitor hemoglobin closely. |
| Pediatric use | Children: 50 units/kg intravenously or subcutaneously three times weekly; adjust by 25 units/kg increments based on hemoglobin response. For anemia in chronic kidney disease: initial 50 units/kg three times weekly. |
| Geriatric use | No specific dose adjustment in elderly; use same dosing principles as adults. Monitor for cardiovascular events and thromboembolism due to higher baseline risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EPOGEN/PROCRIT (EPOGEN/PROCRIT).
| Breastfeeding | Recombinant erythropoietin is excreted in human milk in very low amounts; however, absorption from infant gastrointestinal tract is limited. The M/P ratio is unknown. Consider benefits of breastfeeding, mother's need for drug, and potential adverse effects on infant (e.g., polycythemia, hypertension). Caution advised. |
| Teratogenic Risk | Pregnancy Category C. Animal studies have shown adverse effects (increased fetal mortality, growth retardation) at doses 2-3 times the human dose. No adequate well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: limited data, risk cannot be excluded. Second and third trimesters: may increase risk of hypertensive episodes and thrombotic events, which can compromise placental perfusion. |
■ FDA Black Box Warning
Increased risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence when targeting hemoglobin levels >11 g/dL. Use the lowest dose to avoid red blood cell transfusion. Not indicated for use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
| Serious Effects |
Uncontrolled hypertension; known hypersensitivity to the drug or its components (including albumin human or mammalian cell-derived products); history of pure red cell aplasia (PRCA) following epoetin alfa therapy; use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
| Precautions | Increased mortality, serious cardiovascular events, and thromboembolic events when hemoglobin exceeds 11 g/dL; increased risk of tumor progression or recurrence in cancer patients; increased risk of seizures; pure red cell aplasia (PRCA) due to neutralizing antibodies; severe allergic reactions including anaphylaxis; hypertension; use with caution in patients with uncontrolled hypertension, history of seizures, or known hypersensitivity to albumin (human) or mammalian cell-derived products. |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor hematocrit/hemoglobin weekly until stable, then periodically; blood pressure frequently (risk of hypertension); signs of thrombotic events (especially in patients with underlying risk). Fetal: Ultrasound for growth and amniotic fluid assessment if used in pregnancy; fetal heart rate monitoring if signs of placental insufficiency. |
| Fertility Effects | No direct adverse effects on fertility reported in animal studies. In clinical practice, women with chronic kidney disease may have improved fertility due to correction of anemia and overall health; however, no specific data on epoetin alfa affecting human fertility. |